A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605) Meeting Abstract
| Authors: | Shah, N. J.; Bupathi, M.; Garmezy, B.; McKay, R. R.; Ornstein, M. C.; Figlin, R. A.; Picus, J.; Rank, B. H.; Barata, P. C.; Hammers, H. J.; Hutson, T. E.; Lam, E. T.; Tykodi, S. S.; Zhao, S.; Emamekhoo, H.; Chisamore, M. J.; Mattson, P.; Holm, M.; Iglesias, J. L.; Motzer, R. J. |
| Abstract Title: | A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605) |
| Meeting Title: | 2025 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 5 Suppl. |
| Meeting Dates: | 2025 Feb 13-15 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-10 |
| Language: | English |
| ACCESSION: | WOS:001454744100048 |
| DOI: | 10.1200/JCO.2025.43.5_suppl.TPS609 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS609 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
